UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                  FORM 10-QSB/A

                                   (Mark One)

        [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES
                              EXCHANGE ACT OF 1934

                  FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2004

   [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
                                   ACT OF 1934

              FOR THE TRANSITION PERIOD FROM _________ TO _________

                         COMMISSION FILE NUMBER: 0-32835

                          GAMMACAN INTERNATIONAL, INC.
             (Exact name of registrant as specified in its charter)

              DELAWARE                                     33-0956433
  (State or other jurisdiction of              (IRS Employer Identification No.)
   incorporation or organization)

                              11 BEN GURION STREET
                           54100 GIVAT SHMUEL, ISRAEL
                    (Address of principal executive offices)

                                  972 3 5774475
              (Registrant's telephone number, including area code)

   (Former name, former address and former fiscal year, if changed since last
                                    report)

Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the past 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [ ]

      APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING
                           THE PRECEDING FIVE YEARS:

Indicate by check mark whether the registrant filed all documents and reports
required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act
of 1934 after the distribution of securities under a plan confirmed by a court.
Yes [ ] No [ ]

                      APPLICABLE ONLY TO CORPORATE ISSUERS:

State the number of shares outstanding of each of the registrant's classes of
common equity, as of the latest practicable date: 23,996,512 shares issued and
outstanding as of June 30, 2004.


<PAGE>


ITEM 1. - FINANCIAL STATEMENTS








                           GAMMACAN INTERNATIONAL INC.
                    (Formerly- San Jose International, Inc.)
                      REVISED INTERIM FINANCIAL STATEMENTS
                               AS OF JUNE 30, 2004







<PAGE>


                           GAMMACAN INTERNATIONAL INC.
                    (Formerly- San Jose International, Inc.)
                      REVISED INTERIM FINANCIAL STATEMENTS
                               AS OF JUNE 30, 2004

                                TABLE OF CONTENTS


                                                                            PAGE
        Balance sheets                                                        2
        Statements of operations                                              3
        Statement of stockholder's equity (capital deficiency)                4
        Statements of cash flows                                              5
        Notes to the interim financial statements                           6-9



<PAGE>


                                        GAMMACAN INTERNATIONAL INC.
                                  (Formerly- San Jose International, Inc.)
                                       (A Development Stage Company)
                                               BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                                    JUNE 30,  SEPTEMBER 30,
                                                                                      2004        2003
                                                                                  ----------  -------------
                                                                                  (UNAUDITED)   (AUDITED)
                                                                                  ----------  -------------
<S>                                                                               <C>         <C>
                                           A S S E T S
CURRENT ASSETS -
      cash                                                                        $       --  $          20
                                                                                  ----------  -------------
             T o t a l  current assets                                                    --             20
                                                                                  ----------  -------------
             T o t a l  assets                                                    $       --  $          20
                                                                                  ==========  =============
                    LIABILITIES AND STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)
CURRENT LIABILITIES -
     accounts payable                                                             $  *91,510  $          --
                                                                                  ----------  -------------
             T o t a l  current liabilities                                           91,510             --
                                                                                  ----------  -------------
             T o t a l  liabilities                                                   91,510             --
                                                                                  ----------  -------------
STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY):
     Preferred stock, ($ 0001 par value, 20,000,000 shares authorized:
         none issued and outstanding)                                                     --             --
     Common stock ($ 0001 par value, 100,000,000 and 1,320,000,000
         authorized shares as of June 30, 2004 and September 30, 2003
         respectively; 23,996,512 and 56,281,500 shares issued and outstanding
         as of June 30, 2004 and September 30, 2003,
         Respectively)                                                                 2,400          5,628
     Additional paid-in capital                                                      *75,860         10,032
     Deficit accumulated during development stage                                  *(169,770)       (15,640)
                                                                                  ----------  -------------
             T o t a l  stockholders' equity (capital deficiency)                    (91,510)            20
                                                                                  ----------  -------------
             T o t a l  liabilities and stockholders' equity (capital deficiency) $       --             20
                                                                                  ==========  =============


                                          * Restated, see note 3.


                  THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THE FINANCIAL STATEMENTS.
</TABLE>



                                                     2
<PAGE>

<TABLE>
<CAPTION>
                                                 GAMMACAN INTERNATIONAL INC.
                                          (Formerly- San Jose International, Inc.)
                                                (A Development Stage Company)
                                                  Statements of Operations
                                                         (Unaudited)


                                                                                                             OCTOBER 6, 1998
                                                  NINE MONTHS ENDED                THREE MONTHS ENDED          (INCEPTION)
                                                      JUNE 30                          JUNE 30                   THROUGH
                                            --------------------------       ---------------------------         JUNE 30,
                                               2004            2003             2004             2003              2004
                                            ----------      ----------       ----------       ----------     ---------------
<S>                                         <C>             <C>              <C>              <C>            <C>
General & administrative
     expenses                                *$154,130      $    3,821        *$153,024       $    1,475     *$      169,770
                                            ----------      ----------       ----------       ----------     ---------------
        T o t a l  general &
             administrative expenses           154,130           3,821          153,024            1,475             169,770
                                            ----------      ----------       ----------       ----------     ---------------
Net loss                                    $ (154,130)     $   (3,821)      $ (153,024)      $   (1,475)    $      (169,770)
                                            ==========      ==========       ==========       ==========     ===============
Basic and diluted loss per 1000
     common shares                          $    (2.87)     $    (0.07)      $    (3.16)      $    (0.03)
                                            ==========      ==========       ==========       ==========
Weighted average number of common
     Shares outstanding                     53,650,871      56,281,500       48,389,614       56,281,500
                                            ==========      ==========       ==========       ==========


                                                   * Restated, see note 3.


                          THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THE FINANCIAL STATEMENTS.
</TABLE>


                                                             3
<PAGE>


<TABLE>
<CAPTION>

                                              GAMMACAN INTERNATIONAL INC.
                                        (Formerly- San Jose International, Inc.)
                                             (A Development Stage Company)
                           STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)
                                 FROM OCTOBER 6, 1998 (INCEPTION) THROUGH JUNE 30, 2004
                                                      (Unaudited)


                                                                                             DEFICIT
                                                                                           ACCUMULATED
                                                              COMMON        ADDITIONAL        DURING
                                              COMMON          STOCK           PAID-IN      DEVELOPMENT
                                              STOCK           AMOUNT          CAPITAL         STAGE           TOTAL
                                           ------------    ------------    ------------    ------------    ------------
<S>                                        <C>             <C>             <C>             <C>             <C>
BEGINNING BALANCE                                    --    $         --    $         --    $         --    $         --
STOCK ISSUED FOR CASH ON OCTOBER 6, 1998      1,650,000             165            (155)                             19
STOCK ISSUED FOR CASH ON OCTOBER 9, 1998      2,722,500             272            (107)                            165
STOCK ISSUED FOR CASH ON OCTOBER 10,1998        198,000              20             100                             120
STOCK ISSUED FOR SERVICES ON DECEMBER 1,
  1998                                        9,900,000             990           2,010                           3,000
STOCK ISSUED FOR CASH ON APRIL 7, 1999          561,000              56             284              --             340
NET LOSS                                                                                         (3,444)         (3,444)
                                           ------------    ------------    ------------    ------------    ------------
BALANCE AT SEPTEMBER 30, 1999                15,031,500           1,503           2,132          (3,444)            191
STOCK ISSUED FOR CASH ON SEPTEMBER 30,
  2000                                       41,250,000           4,125             875                           5,000
NET LOSS                                                                                             --              --
                                           ------------    ------------    ------------    ------------    ------------
BALANCE AT SEPTEMBER 30, 2001                56,281,500           5,628             307          (3,444)          5,191
NET LOSS                                                                                         (4,231)         (4,231)
                                           ------------    ------------    ------------    ------------    ------------
BALANCE AT SEPTEMBER 30, 2002                56,281,500           5,628           3,007         (10,783)         (2,148)
CONTRIBUTED CAPITAL                                                               7,025                           7,025
NET LOSS                                                                                         (4,857)         (4,857)
                                           ------------    ------------    ------------    ------------    ------------
BALANCE AT SEPTEMBER 30, 2003                56,281,500           5,628          10,032         (15,640)             20
CANCELLATION OF SHARES AT JUNE 8, 2004      (32,284,988)         (3,228)          3,228
ECONOMIC VALUE OF EXERCISED OPTION,
     see note 5                                                                 *62,600                          62,600
NET LOSS                                                                                     *(154,130)        (154,130)
                                           ------------    ------------    ------------    ------------    ------------
BALANCE AT JUNE 30, 2004                     23,996,512    $      2,400    $     75,860    $   (169,770)   $    (91,510)
                                           ============    ============    ============    ============    ============


                                                * Restated, see note 3.


                        THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THE FINANCIAL STATEMENTS.
</TABLE>


                                                           4
<PAGE>


                                            GAMMACAN INTERNATIONAL INC.
                                      (FORMERLY- SAN JOSE INTERNATIONAL, INC.)
                                           (A Development Stage Company)
                                              STATEMENTS OF CASH FLOWS
                                                    (Unaudited)

<TABLE>
<CAPTION>

                                                                                                          OCTOBER 6,
                                                                                                            1998
                                                         NINE MONTHS ENDED         THREE MONTHS ENDED    (INCEPTION)
                                                               JUNE 30                  JUNE 30            THROUGH
                                                       ---------------------    ----------------------     JUNE 30,
                                                         2004         2003         2004        2003          2004
                                                       ---------   ---------    ----------   ---------    ---------
<S>                                                    <C>         <C>          <C>          <C>          <C>
CASH FLOWS FROM OPERATING
     ACTIVITIES:
     Net loss                                         *$(154,130)  $  (3,821)  *$ (153,024)  $  (1,475)  *$(169,770)
   Adjustments required to reconcile net loss
      to net cash used in operating activities:
         Economic value of exercised option              *62,600                   *62,600                  *62,600
         Common stock issued for services                                                                     3,000
     Increase in accounts payable                        *91,510       3,721    *90,424          1,445      *91,510
                                                       ---------   ---------    ----------   ---------    ---------
     Net cash used in operating activities                   (20)        (90)           --         (30)     (12,660)
                                                       ---------   ---------    ----------   ---------    ---------
CASH FLOWS FROM INVESTING
     ACTIVITIES -
     net cash provided by investing activities                --          --            --          --           --
                                                       ---------   ---------    ----------   ---------    ---------
CASH FLOWS FROM FINANCING
     ACTIVITIES-
     Issuance of common stock and
          contribution to additional paid in capital                                                         12,660
                                                       ---------   ---------    ----------   ---------    ---------
     Net decrease in cash                                    (20)        (90)           --         (30)          --
CASH AT BEGINNING OF PERIOD                                   20         146            --          86           --
                                                       ---------   ---------    ----------   ---------    ---------
CASH AT END OF PERIOD                                  $      --   $      56    $       --   $      56    $      --
                                                       =========   =========    ==========   =========    =========
SUPPLEMENTAL DISCLOSURES OF
     CASH FLOW INFORMATION:
     Interest paid                                     $      --   $      --    $       --   $      --
                                                       =========   =========    ==========   =========
     Income taxes paid                                 $      --   $      --    $       --   $      --
                                                       =========   =========    ==========   =========


                                              * Restated, see note 3.


                      THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THE FINANCIAL STATEMENTS.
</TABLE>


                                                         5
<PAGE>


                           GAMMACAN INTERNATIONAL INC.
                    (Formerly- San Jose International, Inc.)
                          (A Development Stage Company)
                   NOTES TO FINANCIAL STATEMENTS JUNE 30, 2004
                                   (Unaudited)


NOTE 1. - ORGANIZATION AND DESCRIPTION OF BUSINESS

          The Company was incorporated on October 6, 1998, under the laws of the
          State of Delaware, as San Jose International, Inc. The Company has no
          significant revenues and no material operations and in accordance with
          SFAS # 7, the Company is considered a development stage company.

          Through June 30, 2004, the Company has incurred losses in an aggregate
          amount of $169,770. Such losses have resulted from the Company's
          activities as a development stage company. The Company's management
          estimated that it would be able to finance its operations from the
          cash raised in August and November 2004 (see note 7) until September
          30, 2005. Continuation of the Company's current operations after
          utilizing the mentioned reserves until September 30, 2005, is
          dependent upon obtaining financial support from investors until
          profitable results are achieved.

          On August 19, 2004, the name of the company was changed from "San Jose
          International, Inc." into "GammaCan International Inc.".

          During August 2004 the Company acquired, through GammaCan Ltd.,
          (hereafter - "the subsidiary"), from ARP Biomed, Ltd. ("ARP"), an
          Israeli Company, all of ARP's interest in research and development,
          patents and intellectual property (hereafter - "Intellectual
          Property") to provide clinical treatment for various cancer types, in
          consideration for the issuance of 12.5% of the subsidiary's stock to
          ARP. Under the terms of the agreement, which was signed between the
          parties, the Company had to raise $800,000 and lend those funds to the
          subsidiary, which will use those funds to commence clinical trials and
          further research and development utilizing the Intellectual Property.


NOTE 2. - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

          a.   BASIS OF ACCOUNTING

               The accompanying unaudited financial statements of the Company
               have been prepared in accordance with accounting principles
               generally accepted in the United States for interim financial
               information and with the instructions to Form 10-QSB and Item 310
               of Regulation S-B. Accordingly, they do not include all of the
               information and footnotes required by accounting principles
               generally accepted in the United States for complete financial
               statements.

               In the opinion of management, all adjustments (consisting of
               normal recurring accruals) considered necessary for a fair
               presentation have been included. Operating results for the
               nine-month period ended June 30, 2004, are not necessarily
               indicative of the results that may be expected for the year ended
               September 30, 2004. For further information, refer to the
               financial statements and footnotes thereto included in the
               Company's annual report on Form 10-KSB for the year ended
               September 30, 2003.


                                       6
<PAGE>


                           GAMMACAN INTERNATIONAL INC.
                    (Formerly- San Jose International, Inc.)
                          (A Development Stage Company)
             NOTES TO FINANCIAL STATEMENTS JUNE 30, 2004 (continued)
                                   (Unaudited)

NOTE 2. - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued):

          b.   USE OF ESTIMATES

               The preparation of financial statements in conformity with
               generally accepted accounting principles requires management to
               make estimates and assumptions that affect the reported amounts
               of assets and liabilities and disclosure of contingent assets and
               liabilities at the date of the financial statements and the
               reported amounts of revenues and expenses during the reporting
               period. Actual results could differ from those estimates.

NOTE 3. - RESTATEMENT

          The financial statements as of June 30, 2004 have been restated in
          order to reflect, with retroactive effect, certain expenses which were
          incurred during that period and were not accounted for in the previous
          interim financial statements, as of the above date, that were
          published by the company on Form 10Q-SB on July 26, 2004. These
          expenses include the compensation attributed to the fair value of
          options granted to the Company's Officer (see note 5), and expenses
          accrued through June 30, 2004. In addition, the previous financial
          statements were headed "consolidated" financial statements, taking
          into account the consolidation of GammaCan, Ltd (see note 1). Since
          the acquisition of this subsidiary was not completed as of June 30,
          2004, it should not have been consolidated as of that date. The
          deconsolidation of GammaCan Ltd. have no effect, however, on the
          company's financial statements, as GammaCan had no content as of that
          date.

          The effect of this restatement on the financial statements is as
          follows:

                                                              NINE MONTHS ENDED
                                                                JUNE 30, 2004
                                                              -----------------
                                                              $
          a)   NET LOSS:
                  Net loss, as previously reported                       40,307
                  Effect of restatement - increase in general
                    & administrative expenses                           113,823
                                                              -----------------
                  Net loss, as reported in these financial
                    statements                                          154,130
                                                              =================

          b)   NET LOSS PER 1000 COMMON SHARES:
                  Net loss per 1000 common shares as previously
                    reported                                               0.77
                  Effect of restatement                                    2.10
                                                              -----------------
                  Net loss per 1000 common shares, as reported
                    in these financial statements                          2.87
                                                              =================

          c)   CAPITAL DEFICIENCY AT JUNE 30,2004:
                  Balance as previously reported                        (40,287)
                  Effect of restatement:
                    Increase in accumulated deficit                    (113,823)
                    Increase in additional paid-in capital               62,600
                                                              -----------------
                  Balance as reported in these financial
                    statements                                          (91,510)
                                                              =================


                                       7
<PAGE>


                           GAMMACAN INTERNATIONAL INC.
                    (Formerly- San Jose International, Inc.)
                          (A Development Stage Company)
             NOTES TO FINANCIAL STATEMENTS JUNE 30, 2004 (continued)
                                   (Unaudited)

NOTE 4. - GOING CONCERN

          The accompanying financial statements have been prepared assuming that
          the Company will continue as a going concern. The Company has net
          losses for the period from inception (October 6, 1998) through June
          30, 2004 of $169,770. This condition raises substantial doubt about
          the Company's ability to continue as a going concern. The Company's
          continuation as a going concern is dependent on its ability to meet
          its obligations to obtain additional financing as may be required and
          ultimately to attain profitability. These financial statements do not
          include any adjustments that might result from the outcome of this
          uncertainty. As of the company's status after June 30,2004, see notes
          1 and 7.


NOTE 5. - RELATED PARTY TRANSACTIONS

          The Company neither owns nor leases any real or personal property. The
          Company's sole officer and director provides office services without
          charge. On June 21, 2004, a company owned by the Company's sole
          officer and director was granted an option by one of the shareholders
          to purchase 100,000 options at $0.01 per share. The economic value of
          this option, which reflects the compensation for the Company's sole
          officer services, is presented as an expense in the amount of $62,600.
          The option was exercised on August 17, 2004.

          The officers and directors of the Company are involved in other
          business activities and may, in the future, become involved in other
          business opportunities. If a specific business opportunity becomes
          available, such persons face a conflict in selecting between the
          Company and their other business interests. The Company has not
          formulated a policy for the resolution of such conflicts.

          The acquisition of Intellectual Property agreement (see note 1) was
          signed following a Memorandum of Understanding (MOU), which was agreed
          between ARP and a related party. According to the MOU a new company
          shall be incorporated to execute the acquisition of the Intellectual
          Property.


NOTE 6. - STOCK TRANSACTIONS

          On April 20, 2004 the Company effected a 16.5 to 1 forward stock split
          of its Common Stock. All shares and per share amounts have been
          retroactively restated to reflect the 16.5 to 1 stock split. Following
          the forward split the Company also reduced the authorized capital of
          its common stock from 1,320,000,000 shares to 100,000,000 shares.

          On June 8, 2004, the Company's former main stockholder returned
          32,284,988 shares of common stock to the treasury for cancellation.
          Accordingly, an amount of $3,228 was deducted from the "Common stock
          amount" balance and transferred to the "Additional paid in capital"
          balance.



                                       8
<PAGE>


                           GAMMACAN INTERNATIONAL INC.
                    (Formerly- San Jose International, Inc.)
                          (A Development Stage Company)
              NOTES FINANCIAL STATEMENTS JUNE 30, 2004 (continued)
                                   (Unaudited)


NOTE 7. - SUBSEQUENT EVENTS

          On August 13, 2004 the Company entered into subscription agreements
          for the sale of 1,224,998 units at a purchase price of $0.75 per unit
          for a total consideration of $918,750. Each unit consisted of one
          Common Share in the Company and one share purchase warrant, which
          entitles the holder to purchase an additional Common Share for $1.50
          on or before August 13, 2005. The fair value of the warrants estimated
          by using the Black & Scholes option-pricing model is $139,494.

          On November 11, 2004 the company entered into subscription agreements
          for the sale of 978,000 units at a purchase price of $1.25 per unit
          for a total consideration of $1,222,000. Each unit consisted of one
          common share and one share purchase warrant. Each share purchase
          warrant entitles the holder to purchase one additional common share
          for a period of two years after the date of the subscription agreement
          at an exercise price of $1.50 in the first 15 months and $2.00 for the
          next nine months. The fair value of the warrants estimated by using
          the Black & Scholes option-pricing model is $266,629.

          On August 17, 2004, the company's board of directors adopted the 2004
          Employees and Consultants Stock Option Plan (hereafter - the Plan).
          Under the Plan 5,000,000 shares have been reserved for the grant of
          options, which may be issued at the discretion of the Company's board
          of directors from time to time. Under this Plan, each option is
          exercisable to purchase one common share of $ 0.0001 par value of the
          Company. In August 2004 1,450,000 options were granted under the plan
          (of which 1,400,000 were granted to the Company's CEO at that date).
          The exercise price has been determined at $1.3 per share. The options
          may be exercised after vesting and only in accordance with the
          following:

          1.   On the first anniversary commencing the grant date - 25% of the
               options.

          2.   On the last day of each month following the first anniversary of
               the grant date, the option shall vest in equal monthly
               installments for a period of 36 months.

          The expiry date of the above options is on August 18, 2014. The fair
          value of the above options on the date of grant estimated by using
          Black & Scholes option-pricing model is $1,662,964.

          The fair value of the option was based on the following assumptions:
          dividend yield of 0% for all years; expected volatility of 103%;
          risk-free interest rates of 5.4%; and expected lives of 7.88 years.


                                       9
<PAGE>


ITEM 2. MANAGEMENT'S PLAN OF OPERATION

Gammacan International, Inc. (formerly San Jose International, Inc.) was
incorporated under the laws of the state of Delaware on October 6, 1998. Our
fiscal year end is September 30. Our shares of Common Stock are quoted in the
United States on the National Association of Securities Dealers Over the Counter
Bulletin Board (the "OTCBB") and effective June 7, 2004, concurrent with the
forward split of our shares (SEE PART II, ITEM 2), quoted for trading with the
symbol "GCAN".

We currently have no revenue from operations, we are in a start-up phase with
our existing assets and we have no significant assets, tangible or intangible.
There can be no assurance that we will generate revenues in the future, or that
we will be able to operate profitably in the future, if at all. We have incurred
net losses in each fiscal year since inception of our operations.

We have never had any bankruptcy, receivership, or similar proceedings, or any
material reclassification, merger, consolidation or purchase of sale of a
significant amount of assets in the ordinary course of business.

Initially, our business plan was to focus on the business of marketing and
selling custom-designed Spanish colonial doors, windows, frames and related door
hardware. We were planning to sell our products to the home building industry.
During the fourth quarter of our last fiscal year, it became apparent that we
could not readily attract additional financing for our proposed business. We
currently have minimal assets and no capital resources to proceed with our
business plan. These circumstances have significantly impacted our ability to
develop a successful business plan around these products. As an alternative, we
undertook initiatives to identify alternative businesses that may be more
receptive to the financial markets and more likely to achieve profitable
operations.

During our first quarter ended December 31, 2003, we identified a promising
business prospect focused on the seismic acquisition business located in Western
Canada and agreed in principal to acquire all of the shares of two Alberta based
companies. On April 20, 2004, we decided to terminate our efforts to pursue this
proposed acquisition, because it appeared we would not be successful in
obtaining the necessary financing on a timely basis.

NEW BUSINESS OPPORTUNITY

On June 21, 2004 we announced that we signed an agreement with ARP Biomed, Ltd.
("ARP") of Israel to acquire all of ARP's interest in research and development,
patents and intellectual property, to provide clinical treatment for various
forms of cancer. The intellectual property being acquired includes patents in
the United States and certain other countries, pending patents in other
countries, know-how, trial protocols, manuscripts, and certain material
contracts (the "Intellectual Property").

We are acquiring the Intellectual Property through Gammacan, Ltd., a subsidiary
we created specifically for this purpose. 12.5% of the shares of Gammacan with a
deemed value of $100,000 will be issued to ARP as consideration for the purchase
of the Intellectual Property. We will own the remaining 87.5%. In addition, we
have agreed to raise $800,000 and lend those funds to Gammacan, which will then
commence clinical trials and further research and development utilizing the

INTELLECTUAL PROPERTY

Gammacan is planning to focus on the commercialization of an anti-cancer
immunotherapy that appears to be effective in reducing the metastatic spread of
a wide range of cancers. GammaCan's treatment will be based on intravenous
immunoglobulin or IVIG, a safe, non-toxic human plasma-based product, currently
used to treat a variety of immune deficiencies and autoimmune diseases, and
replace the antibodies in people who are unable to produce them. Antibodies are
a naturally occurring, disease fighting protein or compound produced by healthy
people. Intravenous implies the direct injection or delivery, via certain
equipment, into the patient's bloodstream. In preliminary studies, IVIG appears
to boost and strengthen cancer patient's immune systems or antibody levels,
which may be successful in fighting cancer. Although there can be no assurance,
many experts currently view IVIG as a promising future alternative to today's
standard chemotherapy.


                                       10
<PAGE>


CLOSING OF THE ACQUISITION OF THE INTELLECTUAL PROPERTY FROM ARP IS CONTINGENT,
AMONG OTHER THINGS DESCRIBED HEREIN, UPON OUR AB ILITY TO SUCCESSFULLY RAISE THE
$800,000 BEFORE SEPTEMBER 1, 2004. THE DISCUSSION NOTED BELOW REGARDING OUR
PROPOSED CANCER TREATMENT BUSINESS AND OUR PLAN OF OPERATION IS BASED ON THE
ASSUMPTION WE CLOSE WITH ARP. HOWEVER, AT THIS STAGE THERE CAN BE NO ASSURANCE
THAT WE WILL BE SUCCESSFUL IN OUR EFFORTS TO CONCLUDE THIS TRANSACTION.

CURRENT CANCER STATISTICS

Cancer is a disease of the body's cells. Cells in all the tissues and organs of
the body constantly grow and divide to replace old and damaged cells and
maintain the health of the body. Normally, all cells divide and reproduce
themselves in an orderly and controlled manner. In cancer, however, some cells
keep dividing without proper control, forming a lump (which is called a primary
tumour). In leukaemia, or cancer of the blood, too many white blood cells are
produced.

Sometimes cancer cells break away from a tumour and travel to other parts of the
body through the bloodstream or lymphatic system. (The lymphatic system is a
network of fine channels - called lymph vessels - which run throughout the body
and are part of the body's protection against infection and cancer). When the
cancer cells reach other parts of the body they may settle and start to develop
into new tumours. These are known as secondary cancers/tumors or metastases.

There are approximately 2.5 million cases of cancer diagnosed each year in the
Western world alone. Primary tumors, while still localized, can be treated
through surgery and radiation. However, cancers tend to metastasize, or spread,
and form secondary tumors in other locations throughout the body. Most existing
therapeutics or treatments fail because the cancer has metastasized and formed
multiple tumors. At present, nearly 40% of cancer victims with operable tumors
ultimately succumb to metastatic or spreading cancer following surgery.
Frequently, metastasis is triggered by the surgical operation itself. During the
course of surgery, malignant cells may become dislodged from the tumor mass and
enter the circulatory system thus increasing the chance of spreading cancer.

The extent to which metastases occur varies with the type of primary tumor.
Melanoma or skin cancer, breast cancer, lung cancer, colon cancer and prostate
cancer are among the types of cancer that frequently metastasize or spread. When
metastasis takes place, the secondary tumors may form at a number of sites in
the body. Lungs, liver, brain and bone are the most common sites of secondary
tumors.

CURRENT CANCER TREATMENTS

Current cancer treatments include surgery, radiation, and chemotherapy. These
treatments can be ineffective because they are either unable to target cancer
cells throughout the body or they give rise to serious and life-threatening side
effects. Consequently, the medical community is still a long way from winning
the war on cancer. Companies which can provide winning anti-cancer drugs that at
least partially overcome the limitations of current cancer treatments are likely
to be well received by the medical establishment and to achieve a leadership
position in the cancer drug market.

The current alternative to the above noted is the use of various
immunotherapies. Current efforts to deliver effective cancer immunotherapies
generally fall into three categories: cytokines, monoclonal antibodies and
vaccines. Cytokines are medical drugs that stimulate the immune system during
infections. Drug developers have hoped that the same factors that fight
infections could be used to combat cancer cells. Several have been approved for
commercial use, but are generally limited in their application.

Many companies are involved in developing monoclonal antibodies, which are
designed to bind to specific cancer cells and target them for destruction by the
immune system. These products are generally more developed, in terms of market
use and acceptance, than cytokines and several have significant sales. The
products realizing significant sales generally have limited or few side effects.


                                       11
<PAGE>


Cancer vaccines rely on the administration of tumor antigens to elicit an immune
response that remains after the vaccine itself has disappeared. Most cancer
vaccine products currently being developed require the harvesting and processing
of tumor cells to make custom vaccines for each patient. Though this approach
has shown promise in clinical trials, scaling-up manufacture is likely to be
problematic, and these vaccines are generally considered to be a number of years
away from commercial use.

CHEMOTHERAPY

Chemotherapy is the use of anti-cancer drugs to destroy cancer cells. There are
over 50 different chemotherapy drugs and some are given on their own, but often
several drugs may be combined. The type of chemotherapy treatment given for a
particular cancer depends on many things, the type of disease, where in the body
it started, what the cancer cells look like under the microscope and whether
they have spread to other parts of the body.

Chemotherapy is currently the standard treatment for cancer that has or may have
metastasized or spread. Chemotherapy is a systemic treatment, usually
administered intravenously, but can be administered a number of ways, intended
to kill cancer/tumor cells, which have spread to multiple sites. However,
chemotherapy may also kill healthy dividing cells and consequently, may cause
serious side effects. These side effects may include a weakening of a patient's
immune system, and reduction in number of white blood cells which are necessary
to combat bacterial infections, inhibition or slowing of bone marrow cell
growth, which also may be accompanied with slow down in the production of red
blood cells or anemia, the inability to form blood clots, diarrhea, nausea and
hair loss. Generally, these side effects are temporary in nature, but most
patients experience a significant degree of discomfort, and can be long term in
some cases.

Chemotherapy can fail to completely eradicate micro-metastases, or the spreading
of very small cancer tumors, already residing in remote organs (lung, liver,
bone marrow or brain), especially when treatment is discontinued due to
patients' inability to tolerate its side effects. If the cancer is not
completely eradicated, it will likely continue to grow.

The need for an effective, non-toxic treatment to inhibit spreading cancers is
widely recognized and numerous researchers, biotechnology and pharmaceutical
companies are seeking alternatives to chemotherapy drugs. The potential for a
large receptive commercial market exists for a successful approach to inhibiting
spreading cancers without causing serious side effects.

IVIG OR INTRAVENOUS IMMUNOGLOBIN

Our proposed immunotherapy product, if ultimately proven to be successful on a
regulatory and commercial basis, aims to harness the body's immune system, or
its natural defense mechanism to destroy cancer cells.

Immunoglobulins or IVIG is a type of protein found in human blood that helps to
fight off harmful bacteria, viruses and other germs. IVIG is a blood
plasma-derived product containing protective antibodies normally present in the
blood of healthy individuals. IVIG is used to replace the antibodies in people
who are unable to produce them, thereby restoring an almost normal immune
response and helping to prevent or reduce the severity of certain infections. It
is widely used in the treatment of certain autoimmune diseases. Extensive use
over a period of years has demonstrated that IVIG therapy is a safe, non-toxic
therapy with virtually no side effects.

Currently, approximately twenty companies produce IVIG products, achieving
worldwide sales of about $500 million annually. These companies manage pools of
1,000 to 20,000 blood donors who are carefully screened prior to being allowed
to give blood. This donated plasma is also extensively tested for pathogens
prior to use. It is this donated blood plasma that is used to manufacture IVIG,
and through the combining the blood plasma of many individual donors, it is
believed that the resulting combination provides superior therapy than IVIG from
one individual exclusively.

The largest producers of IVIG for the U.S. market are ZLB Bioplasma (a
subsidiary of the Australian blood products company CSL Ltd.), Alpha
Therapeutics, Baxter Healthcare, Bayer Biological Products and Aventis Behring.

IVIG products became commercially available in the early 1980's. There are six
indications or uses approved by the U.S. Food and Drug Administration (FDA), but
IVIG is also used to treat over seventy other "off-label" conditions supported
by a consensus of expert opinion, mostly primary immune deficiencies or
autoimmune neuromuscular disorders. Between 40% and 50% of IVIG prescriptions
are written for off-label indications. Patients receiving IVIG therapy for
primary immune deficiencies usually receive the therapy for life, while patients
receiving IVIG therapy for autoimmune disorders receive the therapy
intermittently over a period of months, and sometimes years, depending on their
condition.


                                       12
<PAGE>


IVIG is generally considered to be an expensive therapy, because it is a natural
product manufactured from whole human blood. A typical dose may consist of five
consecutive days of intravenous administration of 2 grams per kilogram of
patients' body weight. The price of one gram of IVIG has recently ranged from
$18 to $25 on the wholesale level. For a 150 pound (68.2 kilogram) individual,
this translates into a price of between $2,455 and $3,410 for a full two gram
per kilogram body-weight round of treatment. The cost of administration in a
hospital, is also considerable and the total cost for a round of treatment can
thus range from $8,500 to $20,000 per treatment.

PRE-CLINICAL AND PRELIMINARY EXPERIMENTS

ARP's scientists have already conducted certain animal experiments to test the
effectiveness of IVIG immunotherapy in treating cancer, and investigated the
effectiveness of IVIG treatment at various stages of disease progression with
varying dosages and routes of administration. They have made preliminary
progress in understanding the mechanisms under which IVIG appears to fight
cancer.

While these experiments showed promising results, they are preliminary. Use of
IVIG in a commercial setting would be subject to much further substantial and
significant testing, and subject to certain clinical trials required by the FDA
and similar regulatory bodies in other countries.

At this stage however, there can be no assurance that IVIG will evolve into a
successful commercial product, gain acceptance for general use or use as a
replacement for existing therapeutic products, or even be approved for use by
the regulatory authorities.

These early experiments have shown that IVIG treatment appears to reduce
metastases and tumor recurrence for a broad spectrum of cancers, with virtually
no side effects. However, much more testing must be completed. IVIG also appears
to show promise to increase the chances for long term recovery by preventing the
return and spread of cancer. These preliminary experiments have also indicated
that IVIG therapy holds promise as an effective anti-cancer treatment at much
lower doses than is commonly used for treating immune deficiencies. This would
serve to make the treatment more affordable and may enable IVIG immunotherapy to
be used as a cancer prevention measure in high risk populations.

In these preliminary experiments, IVIG also appears to be effective when
administered intravenously, or through several other methods of delivery into
the patient's body. Alternative routes of administration could dramatically
improve ease-of-use, lower the delivered price of treatments, and enable the
treatment of additional conditions.

COMPETITION

Cancer therapeutics represents a major pharmaceutical market with $12 -13
billion in worldwide sales in 2001. Between 1995 and 2000, the market grew at an
average annual rate of 15-20%. Average annual growth is forecast to be 8-10%
through 2015. Despite the large number of patients and the high medical need for
effective treatments, the cancer drug market is ranked only eighth in terms of
drug sales. This corresponds to 4.0% of the total worldwide pharmaceutical
market of $248 billion. In comparison, the 2001 worldwide drug market for
cardiovascular diseases totaled $49 billion (19.5%), central nervous system
diseases $41 billion (16.5%), and alimentary/metabolism diseases $38 billion
(15.3%). The reason for the relatively small size of the cancer drug market is
believed to be primarily due to the lack of effective, safe drugs.

The need for effective, safe cancer drugs has been recently demonstrated by the
successful introductions of new cancer drugs that are relatively effective and
safe. Rituxan(R), for the treatment of certain cancers, was approved in late
1997. By 2002, this product achieved sales of $1.57 billion. Taxotere(R), a
therapeutic product for the treatment of breast cancer and certain types of lung
cancer, was approved in 1996 and achieved sales of $1.35 billion in 2002.


                                       13
<PAGE>


Competition in the area of biomedical and pharmaceutical research and
development is intense and significantly depends on scientific and technological
factors. These factors include the availability of patent and other protection
for technology and products, the ability to commercialize technological
developments and the ability to obtain governmental approval for testing,
manufacturing and marketing. Our Company will compete with other specialized
biotechnology and pharmaceutical firms in the United States, Europe and
elsewhere, many of which are significantly larger than our Company and have
already achieved profitable operations. Many of these companies have focused
their development efforts in the cancer therapeutics area. Many major companies
have also developed or acquired internal capabilities for product development or
made commercial arrangements with other biopharmaceutical companies. These
companies, as well as academic institutions, governmental agencies and private
research organizations, also compete with our Company in recruiting and
retaining highly qualified scientific personnel and consultants.

Competition within this sector itself is increasing, so we will encounter
competition from existing firms that offer competitive solutions in the same
disease area. These competitive companies could develop products that are
superior to, or have greater market acceptance, than the products being
developed by our Company. We will have to compete against other biotech and
pharmaceutical companies with greater market recognition and greater financial,
marketing and other resources.

INTELLECTUAL PROPERTY

Subsequent to closing with ARP, our Company, through GammaCan, will enjoy the
patented protection of IVIG for treating solid tumors through two major U.S.
patents (#5,562,902 and #5,965,130), and additional U.S. and international
patent applications. The latest US patent was on registered on October 1999.
Patent coverage includes a wide range of issues such as: a novel method of
administering to a mammal a preparation of IVIG for inhibiting tumor metastasis
or spreading, for treating primary tumors, and for a broad spectrum of cancerous
diseases. The IVIG preparation to be administered according to this invention
may contain intact or fragmented immunoglobulin molecules. The preparation may
be administered intravenously, directly under the skin or subcutaneous routes,
directly into a cavity (such as an organ or stomach), either as a sole agent or
in combination with other agents or methods, which are commonly used for cancer
treatment.

We believe anyone selling IVIG for treatment of cancer is subject to these
patents.

GOVERNMENT REGULATION - PRODUCT DEVELOPMENT AND COMMERCIAL USE

We will be using and developing biotechnology and pharmaceutical products for
use in treating human diseases. We will be directly affected by governmental
regulations from the United States Food and Drug Administration (FDA) for these
products.

The FDA regulates clinical development and marketing approval of all medical
products intended for human use. The laws and regulations of the FDA place the
burden of proof of safety and efficacy on the manufacture of the product. This
agency possesses extensive experience with its regulatory mechanisms and applies
them to all products, with differing statutes for various categories of
products. Other countries have comparable regulatory agencies to the FDA,
although the specific regulations may differ substantially.

The growth in this industry over the last several decades has been accompanied
by growth in the extent and complexity of the FDA statutes and regulations, and
of the intensity of the FDA's regulations of the development, manufacturing,
distribution, marketing, promotion, advertising and use of regulated products.
In the last decade, the FDA legal and regulatory obstacles to product
commercialization and the penalties of non-compliance have been pivotal factors
in the success or failure of companies in our industry. This is particularly
true for small, emerging companies developing biopharmaceuticals and other
biotechnology products.

RISK FACTORS RELATED TO OUR PROPOSED ACQUISTION

You should carefully consider, in addition to the other information contained in
this quarterly report or in the documents incorporated by reference herein
(particularly our 10KSB for September 30, 2003), the following risk factors,
SHOULD WE CLOSE WITH ARP:


                                       14
<PAGE>


WE WILL REQUIRE A SIGNIFICANT AMOUNT OF ADDITIONAL CAPITAL TO DEVELOP AND
COMMERCIALIZE OUR PRODUCTS.

We will need to raise additional capital in order to finance our anticipated
losses as we continue to develop IVIG. We will also need to finance capital
expenditures for equipment, intellectual property and other asset acquisitions.
Our future capital requirements may be substantial, and will depend on many
factors including:

*    the duration and cost of our clinical trials

*    the progress and scope of our other collaborative and independent research,
     development and clinical projects

*    the size and complexity of these programs

*    the time and costs involved in seeking regulatory approvals

*    the time and costs involved in developing, maintaining and expanding our
     manufacturing facilities

*    our business development and commercialization strategy

*    the costs associated with filing, prosecution and enforcement of patent
     claims

There can be no assurance that capital will be available to us on favorable
terms, or at all. We may choose to raise additional capital from time to time,
either through public or private debt or equity financings, licensing or other
arrangements. Any additional equity financings could be dilutive to our
shareholders and debt financings, if available, may subject us to restrictive
covenants. Any financing done through licensing or other similar arrangements
may require us to relinquish our rights to certain of our technologies, products
or marketing territories. Our failure to raise capital when needed would harm
our business, financial condition and results of operations.

RISKS RELATED TO THE DEVELOPMENT AND COMMERCIALIZATION OF THE IVIG PRODUCT(S)

AT PRESENT, OUR SUCCESS DEPENDS SOLELY ON THE SUCCESSFUL COMMERCIALIZATION OF
IVIG FOR OUR PROPOSED USE AS A CANCER THERAPY ALTERNATIVE.

The successful commercialization of IVIG is crucial for our success. This
proposed product and its potential application is in an early stage of clinical
and manufacturing/process development. It faces a variety of risks and
uncertainties. Principally, these risks include the following:

*    future clinical trial results may show that IVIG at effective doses is not
     well tolerated by the recipients or not efficacious as compared to placebo.

*    future clinical trial results may be inconsistent with ARP's previous
     preliminary testing results. Data from our earlier studies may be
     inconsistent with clinical data.

*    even if IVIG is shown to be safe and effective for its intended purpose, we
     may face significant or unforeseen difficulties in obtaining/manufacturing
     sufficient quantities at or at reasonable prices.

*    our ability to complete the development and commercialization of IVIG for
     our intended use is significantly dependent upon our ability to obtain and
     maintain experienced and committed partners to assist us with obtaining
     clinical and regulatory approvals for, and the manufacturing, marketing and
     distribution of IVIG on a worldwide basis.

*    even if IVIG products are successfully developed, commercially produced and
     receive all necessary regulatory approvals, there is no guarantee that
     there will be market acceptance.

*    our competitors may develop therapeutics or other treatments which are
     superior or less costly than our own with the result that our products,
     even if they are successfully developed, manufactured and approved, may not
     generate significant revenues

If we are unsuccessful in dealing with any of these risks, or if we are unable
to successfully commercialize our IVIG products for some other reason, it would
likely seriously harm our business.


                                       15
<PAGE>


OUR SUCCESS DEPENDS ON OUR ABILITY TO ATTRACT AND RETAIN COLLABORATIVE PARTNERS
OVER WHOM WE HAVE LIMITED CONTROL.

Our business will likely depend on our ability to enter into arrangements with
corporate and academic collaborators relating to the testing, manufacturing,
marketing and commercialization of our products. If successful, we are intending
to license or sublicense that property to others. We are planning to try to have
our partners assume the obligation to manufacture, market and distribute the
resulting products. Consequently, our success depends upon our partners' ability
to perform these tasks. There can be no assurance that we will be able to
establish necessary arrangements on favorable terms, or at all, or that
collaborative agreements will be successful.

OUR SUCCESS DEPENDS ON OUR ABILITY TO PROTECT OUR PROPRIETARY RIGHTS AND OPERATE
WITHOUT INFRINGING UPON THE PROPRIETARY RIGHTS OF OTHERS.

We plan to continue to protect the technology that we consider important to the
development of our business by filing United States and selected foreign patent
applications. We currently hold several patents and pending patent applications
in the United States and corresponding patents and patent applications filed in
certain other countries over IVIG and its proposed use in cancer therapeutics.

The patent position of biopharmaceutical and biotechnology firms, is generally
uncertain and involves complex legal and factual questions. We do not know
whether any of our current or future patent applications will result in the
issuance of any patents. Even issued patents may be challenged, invalidated or
circumvented. Patents may not provide a competitive advantage or afford
protection against competitors with similar technology. Competitors or potential
competitors may have filed applications for, or may have received patents and
may obtain additional and proprietary rights to compounds or processes used by
or competitive with ours. In addition, laws of certain foreign countries do not
protect intellectual property rights to the same extent as do the laws of the
United States or Canada.

Patent litigation is becoming widespread in the biotechnology industry and we
cannot predict how this will affect our efforts to form strategic alliances,
conduct clinical testing or manufacture and market any products under
development. If challenged, our patents may not be held valid. We could also
become involved in interference proceedings in connection with one or more of
our patents or patent applications to determine priority of invention. If we
become involved in any litigation, interference or other administrative
proceedings, we will likely incur substantial expenses and the efforts of our
technical and management personnel will be significantly diverted. In addition,
an adverse determination could subject us to significant liabilities or require
us to seek licenses that may not be available on favorable terms, if at all. We
may be restricted or prevented from manufacturing and selling our products in
the event of an adverse determination in a judicial or administrative proceeding
or if we fail to obtain necessary licenses.

Our commercial success will also depend significantly on our ability to operate
without infringing the patents and other proprietary rights of third parties.
Patent applications are, in many cases, maintained in secrecy until patents are
issued. The publication of discoveries in the scientific or patent literature
frequently occurs substantially later than the date on which the underlying
discoveries were made and patent applications are filed. In the event of
infringement or violation of another party's patent, we may be prevented from
pursuing product development or commercialization.

In addition to patents, we are planning to rely on trade secrets and proprietary
know-how to protect our intellectual property. We are planning to require our
employees, consultants, outside scientific collaborators and sponsored
researchers and other advisors to enter into confidentiality agreements. These
agreements may not provide meaningful protection or adequate remedies in the
event of unauthorized use or disclosure of our proprietary information. In
addition, it is possible that third parties could independently develop
proprietary information and techniques substantially similar to ours or
otherwise gain access to our trade secrets.

WE MAY NOT BE ABLE TO OBTAIN REGULATORY APPROVALS THAT WILL BE NECESSARY TO
COMMERCIALIZE OUR PRODUCTS.

The manufacture and sale of therapeutic products in the United States and Canada
is governed by a variety of statutes and regulations in both countries. These
laws govern the development, testing, manufacture, safety, efficacy, record
keeping, labelling, storage, approval, advertising, promotion, sale and
distribution of biopharmaceutical products. If our products are ultimately
marketed abroad, they would also be subject to extensive regulation by foreign
governments. There can be no assurance that we will be able to obtain the
required regulatory approvals or comply with the applicable regulatory
requirements for any of our IVIG product(s) in development. If we are unable to
obtain necessary regulatory approvals, we may not be able to commercialize our
products.


                                       16
<PAGE>


The IVIG product(s) currently under development will require significant
clinical testing and investment of significant funds prior to commercialization.
Securing regulatory approval requires us to submit extensive clinical data and
supporting information for each indication to establish the product's efficacy.
The process of completing these processes is likely to take a number of years.
Any delay in obtaining approvals may:

*    adversely affect the successful commercialization of our product(s) that we
     develop

*    diminish any competitive advantages that we may obtain

*    adversely affect our receipt of revenues or royalties

Additionally, if we fail to comply with applicable regulatory requirements at
any stage during the regulatory process, we may be subject to sanctions,
including fines, suspensions, product recalls, production suspensions, civil
penalties and criminal prosecution, among other actions.

EVEN IF WE ARE ABLE TO COMMERCIALIZE OUR PRODUCTS, OUR PRODUCTS MAY NOT GAIN
MARKET ACCEPTANCE.

Whether or not any our products gain market acceptance among the medical
community in general, as well as the degree of market acceptance of any of our
products, will depend on a number of factors, including:

-    establishment and demonstration of clinical usefulness and safety
-    cost-effectiveness of the products
-    their potential advantage over alternative products
-    reimbursement policies of governments and third-party payors
-    marketing and distribution support for the products

The success of other products in our market segment in establishing the market,
their pricing, their clinical usefulness or other potential advantages or
disadvantages, will very likely have a major impact on the success of our
product. If our products do not achieve significant market acceptance, our
business, financial condition and results of operations will be harmed. In
addition, third-party payors such as government health administration
authorities, managed care providers and private health insurers are increasingly
challenging the price and examining the cost effectiveness of medical products
and services. If these third-party payors fail to provide adequate coverage for
our products, the market acceptance of the products may be adversely affected.

COMPETITION IN OUR TARGETED MARKETS IS INTENSE AND DEVELOPMENTS BY OTHER
COMPANIES COULD RENDER OUR PRODUCTS OR TECHNOLOGIES NON-COMPETITIVE.

The biotechnology industry is highly competitive and subject to significant and
rapid technological change. Developments by other companies within the industry
could render our products or technologies non-competitive. Some of these
products may be more effective or have an entirely different approach or means
of accomplishing the desired effect than our products. We expect technological
competition from biotechnology companies and academic research institutions to
increase over time.

Many competitors and potential competitors have substantially greater product
development capabilities and financial, scientific, marketing and human
resources than we do. Our competitors may succeed in developing products earlier
and obtaining regulatory approvals and patent protection for such products more
rapidly than we can.


                                       17
<PAGE>


OUR LACK OF COMMERCIAL MANUFACTURING EXPERIENCE MEANS THAT WE WILL HAVE TO INCUR
SUBSTANTIAL COSTS TO DEVELOP MANUFACTURING FACILITIES OR CONTRACT WITH THIRD
PARTIES OVER WHOM WE HAVE LIMITED CONTROL TO DEVELOP OUR PRODUCTS.

In order to be successful, our products must be manufactured and/or obtained in
commercial quantities in compliance with regulatory requirements and at
acceptable costs. We do not have facilities to commercially manufacture our
products under development and we must initially obtain the small amounts of
products we require for clinical studies from contract manufacturing companies.
In order to manufacture our products in commercial quantities, we will need to
develop manufacturing facilities or contract with third parties to manufacture
our products. We may not be able to develop or otherwise secure access to
appropriate facilities and manufacturing contracts with third parties may not be
available to us on favorable terms, if at all.

OUR LACK OF MARKETING AND SALES EXPERIENCE MEANS THAT WE MUST RELY ON THE
EFFORTS OF OTHERS TO COMMERCIALIZE OUR PRODUCTS.

We do not have a marketing, sales or distribution capability. We intend to enter
into arrangements with third parties to market and sell most of our products. We
may not be able to enter into marketing and sales arrangements with others on
favorable terms, if at all. To the extent that we enter into marketing and sales
arrangements with other companies, our revenues will depend on the efforts of
others and which efforts may not be successful. If we are unable to enter into
satisfactory third-party arrangements, then we must develop a marketing and
sales force, which may need to be substantial in size, in order to achieve
commercial success for any product. We may not successfully develop or obtain
the necessary marketing and sales experience or have sufficient resources to do
so. If we fail to establish successful marketing and sales capabilities or to
enter into successful marketing arrangements with third parties, our business,
financial condition and results of operations will be materially adversely
affected.

OUR DEVELOPMENT PROGRAMS AND FUTURE PRODUCTS SUBJECT US TO THE RISK OF PRODUCT
LIABILITY CLAIMS FOR WHICH WE MAY NOT BE ABLE TO OBTAIN ADEQUATE INSURANCE
COVERAGE.

Human therapeutic products involve the risk of product liability claims and
associated adverse publicity. Currently, our principal risks relate to
participants in our clinical trials who may become ill or suffer unintended
consequences from our IVIG therapeutic. If we ultimately are successful in
commercializing a product, claims might be made directly by consumers,
healthcare providers or by pharmaceutical companies or others selling or using
our products. There can be no assurance that we will be able to obtain or
maintain sufficient and affordable insurance coverage for any of these claims
and, without sufficient coverage, any claim brought against us could have a
materially adverse effect on our business, financial condition or results of
operations.

OUR BUSINESS MAY BE HARMED IF WE CANNOT OBTAIN SUFFICIENT QUANTITIES OF RAW
MATERIALS.

We will be dependent on outside vendors for our entire supply of IVIG. If the
third party suppliers were to cease production or otherwise fail to supply us
with quality IVIG and we were unable to contract on acceptable terms for these
services with alternative suppliers, our ability to produce our products, and to
conduct testing and clinical trials would be adversely affected.

IF WE ARE UNABLE TO ENROLL SUFFICIENT PATIENTS AND CLINICAL INVESTIGATORS TO
COMPLETE OUR CLINICAL TRIALS, OUR DEVELOPMENT PROGRAMS COULD BE DELAYED OR
TERMINATED.

The rate of completion of our clinical trials, and those of our collaborators,
is significantly dependent upon the rate of enrollment of patients and clinical
investigators. Patient enrollment is a function of many factors, including:

-    efforts of the sponsor and clinical sites involved to facilitate timely
     enrollment
-    patient referral practices of physicians - design of the protocol
-    eligibility criteria for the study in question
-    perceived risks and benefits of the drug under study
-    the size of the patient population
-    availability of competing therapies
-    availability of clinical trial sites
-    proximity of and access by patients to clinical sites


                                       18
<PAGE>


We may have difficulty obtaining sufficient patient enrollment or clinician
participation to conduct our clinical trials as planned, and we may need to
expend substantial additional funds to obtain access to resources or delay or
modify our plans significantly. These considerations may lead us to consider the
termination of ongoing clinical trials or development of a product for a
particular indication.

OUR COLLABORATIONS WITH SCIENTIFIC ADVISORS AND ACADEMIC INSTITUTIONS MAY BE
SUBJECT TO RESTRICTION AND CHANGE.

We plan on working with scientific advisors and academic collaborators who will
assist us in our ongoing research and development efforts. These scientists will
not be our employees and may have other commitments that limit their
availability to us. If a conflict of interest arises between their work for us
and their work for another entity, we may lose their services. In addition,
although we plan on our scientific advisors and academic collaborators signing
non-disclosure agreements, it is possible that valuable proprietary knowledge
may become publicly known which would compromise our competitive advantage.

WE ARE SUBJECT TO INTENSE COMPETITION FOR SKILLED PERSONNEL AND THE LOSS OF KEY
PERSONNEL OR THE INABILITY TO ATTRACT AND RETAIN ADDITIONAL PERSONNEL COULD
IMPAIR OUR ABILITY TO CONDUCT OUR OPERATIONS.

We will be highly dependent on the principal members of our management and
scientific staff, the loss of whose services might adversely impact the
achievement of our objectives and the continuation of existing collaborations.
In addition, recruiting and retaining qualified scientific personnel to perform
future research and development work will be critical to our success. There is
currently a shortage of employees with expertise in our areas of research and
clinical and regulatory affairs, and this shortage is likely to continue.
Competition for skilled personnel is intense and turnover rates are high. Our
ability to attract and retain qualified personnel may be limited.

ADDITIONAL RISKS RELATED TO OWNING OUR SHARES

OUR SHARE PRICE WILL LIKELY BECOME HIGHLY VOLATILE.

Factors such as announcements of technological innovations, new commercial
products, patents, the development of technologies (by us or others), results of
clinical studies, regulatory actions, publications, financial results or public
concern over the safety of our products or other related products and other
factors could have a significant effect on the market price of our common
shares.

PLAN OF OPERATION

The following discussion of the financial condition, results of operations, cash
flows and changes in financial position of our Company should be read in
conjunction with our most recent financial statements and notes appearing
elsewhere in this Form 10-QSB; and our Form 10KSB for September 30, 2003.

As of the date of filing of our 10Q for June 30, 2004, we had not closed the
transaction with ARP described in this report. As noted herein, the closing of
the transaction with ARP is subject to our Company raising $800,000 and
concurrently lending it to GammaCan prior to September 1, 2004. It is also
subject to completion of a suitable employment agreement with a certain key
individual, among other things.

If we cannot close this transaction, we do not anticipate making any major
purchases of capital assets in the next 12 months, or conducting any research
and development directly, nor will we hire additional employees in the next 12
months.

This foregoing discussion regarding our Plan of Operation is based on the
assumption we close with ARP.

CLINICAL TRIALS

GammaCan's initial focus over the next several years is to demonstrate efficacy
of IVIG cancer immunotherapy in human clinical trials. Efficacy is the ability
of a drug or other treatment to produce the desired result when taken by its
intended users. If ultimately proven to be successful, and there can be no
assurance that it will be, GammaCan could be well-positioned to enter a
licensing agreement with a major pharmaceutical partner for commercial market
development and sales.


                                       19
<PAGE>


IVIG immunotherapy will require regulatory approval before being commercially
marketed for human therapeutic use. Clinical trials generally include three
phases that together may take several years to complete. Phase I clinical
studies (toxicity trials) are primarily conducted to establish safety. Phase II
studies are designed to determine preliminary efficacy. Phase III studies are
conducted to optimize therapeutic efficacy in a statistically significant manner
at the levels of optimal dose, method of delivery into the body or route, and
schedule of administration. Once clinical trials are completed successfully,
products may receive regulatory approval.

Subject to closing with ARP and raising sufficient capital, GammaCan plans to
begin enrolling patients within the quarter following closing, for a Phase II
study using IVIG immunotherapy as an adjunct treatment for a wide range of
cancers. Since IVIG is an established, safe therapy, we will not be required to
conduct Phase I studies. Phase II clinical trials will be conducted at two or
three medical centers in Israel. It is expected to take six months to enroll
patients. We are planning on including several different cancers in the trial,
some of which metastasize and progress quickly, so statistically significant
preliminary results may be available after one year. We will continue to monitor
patients for at least two years. If successful or promising, and at this
preliminary stage there is no assurance they will be, results of these clinical
trials will be used to enter into discussions with a major pharmaceutical
partner to work with us to potentially commercialize the product(s) (SEE
"Business Strategy).

GammaCan estimates that it will take about thirty months to complete Phase III
trials and receive regulatory approval to market IVIG immunotherapy. In 2007,
when GammaCan anticipates IVIG immunotherapy may be available commercially for
treating cancer, provided the trials are successful, clinical trial results and
applications for the product(s) will be published. These studies will enable
physicians to study and ultimately prescribe IVIG therapy for a range of
specific cancers. Subsequent post-marketing studies would then also be conducted
to further evaluate efficacy for different population groups and different
stages of disease progression.

GammaCan is also planning to conduct additional clinical trials to test new
formulations of IVIG and to test IVIG immunotherapies for different cancers at
different stages of disease progression with varying dosages and routes of
administration. GammaCan's goal is to partner with a pharmaceutical company to
conduct these further Phase II and Phase III trials, in order to attain
broad-based regulatory approval.


LONG TERM BUSINESS STRATEGY

As noted previously, if IVIG shows significant promise thorough clinical trials,
GammaCan plans to ultimately seek a strategic commercial partner with extensive
experience commercializing and marketing cancer drugs. It is envisaged that the
partner would be responsible to ensure that regulatory approvals are achieved in
a timely manner and that GammaCan's IVIG immunotherapies penetrate the cancer
market rapidly following FDA approval. This planned strategic partnership could
provide a marketing and sales infrastructure for GammaCan's products as well as
financial and operational support for global trials and other FDA requirements
concerning future clinical development. GammaCan's pharmaceutical partner could
also provide capital and expertise that would enable the partnership to develop
new formulations of IVIG cancer immunotherapy suitable for patients at different
stages of disease progression.

GammaCan also plans to establish a close relationship with at least one producer
of IVIG products to co-develop new product formulations and to provide our
Company with IVIG for further pre-clinical testing and clinical trials. There is
considerable expertise involved in producing IVIG and significant expense and
infrastructure involved in collecting and testing blood. Working together with a
partner in the industry will expedite new product formulation, production and
ensure a safe standardized product.

OTHER RESEARCH AND DEVELOPMENT PLANS

In addition to conducting early-stage clinical trials, GammaCan plans to conduct
research to develop alternative delivery systems, to determine the optimal
dosage for different patient groups and to investigate alternative sources of
immunoglobulin other than human plasma. GammaCan plans to conduct research to
isolate the fraction of IVIG, which is responsible for its anti-metastasis
effects and to develop a synthetic version of IVIG. These formulations will be
suitable for:


                                       20
<PAGE>


*    Low-dose, preventative therapy for disease-free, high-risk individuals,

*    Strong dose for use in conjunction with surgery and other cancer
     treatments, and

*    Maintenance dose for use to prevent recurrence of cancer growth.

Our plan is to patent any successful inventions resulting from our further
research activities.

PERSONNEL

During the next 12 months, if we close our transaction with ARP, our company
plans to function with a small management staff of 3 persons. During this time,
GammaCan will focus on managing Phase II clinical trials and establishing
preliminary relationships with potential commercial partners. A CEO, a senior
pharmaceutical marketing professional and a business development director will
be recruited. The subsidiary GammaCan will also hire a VP-Regulatory Affairs who
will be responsible for coordinating the clinical trials and plan to hire a
Chief Medical Officer responsible for supervising the trials and assuring proper
patient monitoring. These two positions will initially be on a part-time basis
and will become full-time positions as activities expand in over the next 12
months. We are also planning to hire a CFO on a part-time basis. This position
will also become a full time position in 2005. Prof. Shoenfeld, a key person
involved in the development and preliminary trials with IVIG, is intending to
serve as GammaCan's Chief scientific officer on a part-time basis. The Company
plans to hire additional administrative staff as needed. Our CEO and CFO will
also function in the same positions in our GammaCan subsidiary.

FACILITIES

During the quarter, we relocated our operations to Suite 1500, 800 West Pender
Street, Vancouver, B.C. Canada, V6C 2V6. We occupy less than 100 square feet on
a rent free basis.

Subsequent to closing the transaction with ARP, GammaCan plans to relocate and
establish office and laboratory facilities of approximately 150 square meters
(1,700 square feet) within six months and to add another 250 square meters of
space in 2006 or 2007 as the Company grows. During an initial period, the
Company plans to rent small offices.

PLANNED EXPENDITURES

Our planned expenditures (000's) for the next 12 months, assuming we close the
ARP transaction include:

R&D


    Salaries                               $   70
    Contract                                  200
    Clinical Trials                           400
    Patents and IP                             20
    Other                                     120

Marketing
    Salaries                                  140
    Other                                     160

General & Admin
    Salaries                                  150
    Consultants                                40
    Travel                                     50
    Professional fees                         180
   Office and other                           200
                                           ------
Total                                      $1,730
                                           ======


                                       21
<PAGE>


THE $800,000 WE ARE REQUIRED TO RAISE TO CLOSE THE TRANSACTION WITH ARP IS ONLY
SUFFICIENT TO FUND OUR PROPOSED OPERATIONS AND PLANNED EXPENDITURES FOR 5
MONTHS.

THERE CAN BE NO ASSURANCE THAT WE WILL BE SUCCESSFUL IN OUR EFFORTS TO CONCLUDE
THE ARP TRANSACTION OR ANY OTHER TRANSACTION TO OBTAIN OR BUILD A VIABLE AND
PROFITABLE BUSINESS, OR THAT WE WILL B E ABLE TO RAISE SUFFICIENT DEBT OR EQUITY
FINANCING TO DEVELOP OUR BUSINESS(S).

RESULTS OF OPERATIONS

At June 30, 2004, we had a revised working capital deficiency of $91,510
compared to working capital of $20 at September 30, 2003.

At June 30, 2004, we had $nil assets. This compares with total assets at
September 30, 2003 of $20, which was comprised solely of cash.

Revenues were -0- for the nine months and the third quarter ending June 30,
2004, and -0- for the comparable periods in 2003. Revised general and
administrative expenses were $154,130 for the nine months ended June 30, 2004
versus $3,821 for the same period in 2003. For the third quarter ended June 30,
2004, general and administrative expenses were $153,024 and $1,475 in 2003.
Expenses for the 2004 third quarter include $70,657 payable to consultants for
services related to identification and assistance in consummating the
transaction with ARP.

We have not had revenues from inception. Our company has no assets and without
additional capital, we may not be able to survive beyond the next quarter.
Although there may be insufficient capital to execute our business plan, we
expect to survive with funding from sales of securities and, as necessary or
from shareholder loans. There is no assurance we will be successful in raising
the necessary funding or on terms that are acceptable to our company.

ITEM 3 -  CONTROLS AND PROCEDURES

Our sole officer at the time of the initial filing of this Form 10-QSB evaluated
the effectiveness of our disclosure controls and procedures (as defined in Rule
13a-14c under the Securities and Exchange Act of 1934, as amended) within 90
days of the filing date of this Form 10-Q (the Evaluation Date). Based on that
evaluation, he concluded that, as of the Evaluation Date, our Company had
sufficient procedures for recording, processing, summarizing and reporting
information that is required to be disclosed in its reports under the Securities
and Exchange Act of 1934, as amended.

Since the Evaluation Date, there have not been any significant changes to our
internal controls or other factors that could significantly affect these
controls, including any corrective actions with regard to significant
deficiencies and material weaknesses.

                            PART II OTHER INFORMATION

ITEM 1.   LEGAL PROCEEDINGS

None


                                       22
<PAGE>


ITEM 2.   CHANGES IN SECURITIES

On May 28, 2004, a 16.5 for 1 forward split was affected with the Delaware
Secretary of State of our issued and outstanding Common Stock. As a result, it
increased from 3,411,000 shares to 56,281,500 shares. Additionally, our
authorized Common Stock increased from 80,000,000 shares to 100,000,000 shares
(SEE ITEM 4). The forward split took effect with the OTC Bulletin Board on June
8, 2004 under the new stock symbol SJOS. Our new CUSIP number is 798212 20 5.

On June 8, 2004, Mr. Greenwood, our former director, tendered 32,284,988 shares
beneficially held by him to treasury for cancellation. Subsequent to the
cancellation, there are 23,996,512 issued and outstanding Common Shares in our
Company.

ITEM 3.   DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4.   SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

On January 19, 2004, our company's sole director approved Amendments to our
company's Certificate of Incorporation as follows:

(i)  an amendment to the Certificate of Incorporation to change the name of our
company to "Conquest Geoservices, Inc." to more accurately reflect our company's
proposed future business;

(ii) an amendment to our Certificate of Incorporation to effect a forward split
(the "Forward Split") of our company's Common Stock including the authorized
capital increase from 80,000,000 shares of Common Stock to 880,000,000 shares of
Common Stock and correspondingly the issued and outstanding capital increase
from 3,411,000 shares of Common Stock to 37,521,000 shares of Common Stock; and

(iii) an amendment to our Certificate of Incorporation to create 20,000,000
Class A Special Voting Shares.

On April 20, 2004, we decided to terminate our efforts to pursue the proposed
acquisition of Conquest, because it appeared we would not be successful in
obtaining the necessary financing on a timely basis. Accordingly, as of the same
date, our sole director passed a director's resolution to declare that these
Proposed Amendments are no longer advisable and that we will not seek
shareholders' approval of the Proposed Amendments. Approval from shareholders
holding a majority of our Common Stock was never obtained, and we did not file a
Certificate of Amendment with the Secretary of State for the State of Delaware.


Concurrent with the termination of this proposed acquisition, our sole director
approved the following resolutions and gave notice to our stockholders to:

(i)  effect a 16.5 to 1 forward split (the "Forward Split") of our Common Stock,
such that our issued and outstanding Common Stock increase from 3,411,000 shares
to 56,281,500 shares, and our authorized capital increase from 80,000,000 shares
of Common Stock and 20,000,000 shares of Preferred Stock to 1,320,000,000 shares
of Common Stock and 20,000,000 shares of Preferred Stock;

(ii) reduce the authorized share of our Common Stock following the Forward Split
from 1,320,000,000 shares of Common Stock to 100,000,000 shares of Common Stock
so that our authorized capital consist of 100,000,000 shares of Common Stock.

On April 20, 2004, the shareholder holding a majority of our Common Stock
approved by way of a written consent resolution an Amendment to the Certificate
of Incorporation to carry out the Forward Split and the subsequent reduction of
the authorized shares of Common Stock.

The Forward Split and subsequent reduction of the authorized shares of Common
Stock was affected with the Delaware Secretary of State on May 28, 2004.


                                       23
<PAGE>


ITEM 5.   OTHER INFORMATION

In conjunction with the transaction with ARP, Mr. Greenwood, our former
director, sold 699,996 shares beneficially held by him to an individual who is
intended to be a key employee of GammaCan.

On June 17, 2004, Mr. Christopher Greenwood resigned as our sole Officer and
Director, and was replaced by Mr. David Stephens. Mr. Stephens has been
self-employed as an independent business consultant since 1999, and provides
consulting services in the areas of finance, operations and regulatory
disclosure. Previous to this, he provided services to a number of public and
private companies conducting business in telecommunications, hydrocarbon
exploration and services, and biotechnology. He has also served in an executive
capacity for several publicly listed financial institutions and emerging
technology companies.

Concurrent with the resignation of Mr. Greenwood, we relocated our operations to
Suite 1500, 800 West Pender Street, Vancouver, B.C., Canada, V6C 2V6. Our phone
number is (780) 708-0495 and our fax number is (604) 605-1173. We anticipate
that we may relocate again upon closing of the transaction with ARP.

On July 5, 2004, our Director adopted a resolution changing the name of our
Company to GammaCan International Inc., to better reflect our business. The name
change was approved by the consent of a majority of our stockholders, which was
obtained on July 8, 2004.


ITEM 6.   EXHIBITS AND REPORTS ON FORM 8-K

(a)  Pursuant to Rule 601 of Regulation SB, the following exhibits are included
     herein or incorporated by reference.

3(i) Articles of Incorporation*

3(ii) Bylaws *

10 Sale of Intellectual Property Agreement dated June 11, 2004 between Gammacan,
Ltd. and ARP Biomed, Ltd. ***

31.1 - Certification of Principal Executive Officer pursuant to Rule 13a-14 and
Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as
amended

31.2 - Certification of Principal Financial Officer pursuant to Rule 13a-14 and
Rule 15d 14(a), promulgated under the Securities and Exchange Act of 1934, as
amended

32.1 - Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer)

32.2 - Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer)

99 Certificate of Amendment of Certificate of Incorporation **

* Incorporated by reference - refer to the company's initial registration
statement
** Incorporated by reference - refer to the company's 8-K filed June 8, 2004
*** Incorporated by reference - refer to the company's 8-K filed June 22, 2004

(b)  Reports on Form 8-K

April 27, 2004 reporting the termination of a proposed acquisition and
amendments to the company's Articles of Incorporation

June 8, 2004 reporting the 16.5 for 1 forward split of the Company's issued
Common Stock and the net increase in the Company's authorized Common Stock by
20,000,000 shares

June 22, 2004 reporting the change of address for the Company, the resignation
and appointment of the Company's sole officer and director, cancellation of
32,284,988 Common Shares, and the acquisition of intellectual property from ARP
Biomed, Ltd.


                                       24
<PAGE>


                                   SIGNATURES

Pursuant to the requirements of Section 12 of the Securities Exchange Act of
1934, the Company has duly caused this disclosure statement to be signed on its
behalf by the undersigned, thereunto duly authorized.




                                                 GAMMACAN INTERNATIONAL, INC.

February 9, 2005
                                                 /s/ TOVI BEN ZEEV
                                                 -------------------------------
                                                 Tovi Ben Zeev,
                                                 Chief Financial Officer





                                       25